Muscle-invasive bladder cancer (MIBC)

Authored by Open Medicine, published on 2026-07-24 22:17:48.0

This algorithm outlines a contemporary management approach for muscle-invasive bladder cancer, stratifying patients by cisplatin eligibility and surgical candidacy to guide the use of neoadjuvant chemotherapy, perioperative immunotherapy, or bladder-preserving chemoradiation. It incorporates emerging phase III data supporting perioperative checkpoint inhibitors and antibody–drug conjugates, along with established adjuvant immunotherapy for high-risk residual disease after cystectomy.

  1. MIBC
    This node defines the disease context and overarching management framework (cystectomy vs bladder preservation; use of perioperative systemic therapy; adjuvant immunotherapy for high-risk disease). Major guidelines directly support the overall approach.
    • Cystectomy Eligible
      • Cis-Gem +/- Durvalumab Dd MVAC (Cis-eligible)
        • Cystectomy
          • Observation OR Durvalumab (NIAGARA) OR EV + Pembro (EV-303/304) OR Adj Nivolumab/Pembrolizumab (post NAC and ≥ ypT2, or N1-3)
      • EV + Pembrolizumab (Cis-ineligible)
        • Cystectomy
          • Observation OR Durvalumab (NIAGARA) OR EV + Pembro (EV-303/304) OR Adj Nivolumab/Pembrolizumab (post NAC and ≥ ypT2, or N1-3)
      • EV + Pembrolizumab (Cis-eligible)
        • Cystectomy
          • Observation OR Durvalumab (NIAGARA) OR EV + Pembro (EV-303/304) OR Adj Nivolumab/Pembrolizumab (post NAC and ≥ ypT2, or N1-3)
    • Cystectomy Ineligible
      • Chemo w/Concurrent XRT (Cis or 5FU/Mitomycin or Gemcitabine)
tosprivacyNCCN Bladder Cancer GuidelinesEAU Muscle-invasive and Metastatic Bladder Cancer GuidelinesHow to Treat Bladder Cancer – Drs. Stephanie Berg (Medical Oncologist) & Joshua Meeks (Urologist)Uromigos Episode 490: Systemic Therapy Only in Patients with MIBCUromigos Episode 486: ctDNA and utDNA Data in Peri-operative Urothelial cancerUromigos Episode 483: ASCO GU 2026 - KEYNOTE B15: Neoadjuvant EVP vs Gem/Cis in Cis-eligible MIBCThe Role of Neoadjuvant Chemotherapy in Bladder Preservation Approaches in Muscle-Invasive Bladder CancerESMO 2024: Invited Discussant: A Randomized Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder Cancer (NIAGARA)Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?ESMO 2025: EV-103 Cohort K: Efficacy and Safety of Enfortumab Vedotin with or without Pembrolizumab in Cisplatin-ineligible patients with Previously Untreated Locally Advanced or Metastatic Urothelial Cancer with a Median Follow-up of ≈3.5 YearsAdjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder CancerPerioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/​KEYNOTE-905/​EV-303)Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaRadiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer